

# Jonathan C Hsu, Mas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3124831/publications.pdf>

Version: 2024-02-01

129  
papers

2,613  
citations

257450

24  
h-index

223800

46  
g-index

133  
all docs

133  
docs citations

133  
times ranked

3908  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ablation of mitral annular flutter ablation utilizing a left atrial anterior line versus a lateral mitral isthmus line: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 63, 87-95.	1.3	9
2	Association between early recurrences of atrial tachyarrhythmias and long-term outcomes in patients after repeat atrial fibrillation ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 64, 323-331.	1.3	4
3	Association of heart failure with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the national inpatient sample of 62,980 procedures. <i>Europace</i> , 2022, 24, 1451-1459.	1.7	7
4	To Occlude or Not to Occlude the Left Atrial Appendage in Women—Reply. <i>JAMA Cardiology</i> , 2022, , .	6.1	0
5	Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database. <i>PLoS ONE</i> , 2022, 17, e0263903.	2.5	3
6	Characteristics and outcomes of recurrent atrial fibrillation after prior failed pulmonary vein isolation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 64, 715-722.	1.3	5
7	In vivo porcine characterization of atrial lesion safety and efficacy utilizing a circular pulsed-field ablation catheter including assessment of collateral damage to adjacent tissue in suprathreshold ablation applications. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1480-1488.	1.7	10
8	Performance and acute procedural outcomes of the EnSite Precision <sup>®</sup> cardiac mapping system for electrophysiology mapping and ablation procedures: results from the EnSite Precision <sup>®</sup> observational study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 141-151.	1.3	4
9	Association of advanced age with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the National Inpatient Sample of 36,065 procedures. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 219-226.	1.3	6
10	Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 142, 66-73.	1.6	27
11	Contemporary procedural trends of Watchman percutaneous left atrial appendage occlusion in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 83-92.	1.7	20
12	Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. <i>JAMA Network Open</i> , 2021, 4, e2035470.	5.9	0
13	Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 77, 861-871.	2.8	62
14	A simple improvement on existing technology to enhance transeptal puncture and left atrial access using large diameter sheaths for mapping, ablation, and LAA occlusion procedures. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 735-736.	1.7	1
15	Electrical Substrate Ablation for Refractory Ventricular Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008868.	4.8	10
16	Successful use of a prophylactic cerebral protection device via the radial artery during left atrial appendage occlusion device implantation in a patient with a mitral valve mass. <i>HeartRhythm Case Reports</i> , 2021, 7, 242-245.	0.4	0
17	Racial Disparities in In-Hospital Adverse Events Among Patients With Atrial Fibrillation Implanted With a Watchman Left Atrial Appendage Occlusion Device: A US National Perspective. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009691.	4.8	16
18	Association between specific antiarrhythmic drug prescription in the post-procedural blanking period and recurrent atrial arrhythmias after catheter ablation for atrial fibrillation. <i>PLoS ONE</i> , 2021, 16, e0253266.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Fasciculoventricular and atrioventricular accessory pathways in patients with Danon disease and preexcitation: A multicenter experience. <i>Heart Rhythm</i> , 2021, 18, 1194-1202.	0.7	7
20	Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection. <i>Case Reports in Cardiology</i> , 2021, 2021, 1-3.	0.2	8
21	Association of chronic kidney disease and end-stage renal disease with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: Insights from the national inpatient sample of 36,065 procedures. <i>Heart Rhythm O2</i> , 2021, 2, 472-479.	1.7	14
22	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. <i>JAMA Cardiology</i> , 2021, 6, 1275.	6.1	49
23	Pericardial effusion requiring intervention in patients undergoing percutaneous left atrial appendage occlusion: Prevalence, predictors, and associated in-hospital adverse events from 17,700 procedures in the United States. <i>Heart Rhythm</i> , 2021, 18, 1508-1515.	0.7	20
24	Computational ECG mapping and respiratory gating to optimize stereotactic ablative radiotherapy workflow for refractory ventricular tachycardia. <i>Heart Rhythm O2</i> , 2021, 2, 511-520.	1.7	17
25	Outpatient Prescription Practices in Patients with Atrial Fibrillation (From the NCDR PINNACLE) <i>TJ ETQq1 1 0.784314rgBT /Oyerlock 10</i>	1.6	4
26	Defibrillation Safety Margin Testing in Patients With Congenital Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1145-1154.	3.2	2
27	Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAViATA. <i>International Journal of Cardiology</i> , 2021, 340, 26-33.	1.7	4
28	Atrial fibrillation associated with heart failure treated by a 2-lead CRT-DX system (BIO-AffectDX): Study design and clinical protocol. <i>Heart Rhythm O2</i> , 2021, 2, 642-650.	1.7	0
29	Catheter Ablation for Hospitalized Atrial Fibrillation Patients with Reduced Systolic Function: Analysis of Inpatient Mortality, Resource Utilization and Complications. <i>Journal of Atrial Fibrillation</i> , 2021, 13, 2480.	0.5	1
30	Association between implantable cardioverter-defibrillator and survival in patients awaiting heart transplantation: A meta-analysis and systematic review. <i>Heart Rhythm O2</i> , 2021, 2, 710-718.	1.7	3
31	Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 279-288.	1.3	1
32	Role of adjunctive posterior wall isolation in patients undergoing atrial fibrillation ablation: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 58, 77-86.	1.3	16
33	Ventricular arrhythmias in patients with biventricular assist devices. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 58, 243-252.	1.3	6
34	Comparison of Outcomes After Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 136, 62-70.	1.6	13
35	Ventricular Tachycardia Storm Originating From Moderator Band Requiring Extracorporeal Membrane Oxygenation. <i>JACC: Case Reports</i> , 2020, 2, 946-950.	0.6	2
36	Effect of closed loop stimulation versus accelerometer on outcomes with cardiac resynchronization therapy: the CLASS trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 61, 479-485.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. <i>International Journal of Cardiology</i> , 2020, 321, 88-94.	1.7	3
38	Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis. <i>HeartRhythm Case Reports</i> , 2020, 6, 761-764.	0.4	11
39	Clinical factors associated with baseline history of atrial fibrillation and subsequent clinical outcomes following initial implantable cardioverter-defibrillator placement. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 542-550.	1.2	3
40	Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes. <i>Heart Rhythm</i> , 2020, 17, 1878-1886.	0.7	3
41	Spontaneous Left Atrial Thrombus Formation on the Catheter Delivery System During WATCHMAN Implantation. <i>JACC: Case Reports</i> , 2020, 2, 444-448.	0.6	0
42	P2Y <sub>12</sub> inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2020, 106, 575-583.	2.9	13
43	Left Atrial Appendage Triggers in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 31-33.	3.2	1
44	Prevalence, predictors and complications with defibrillation threshold testing in pediatric patients: Results from the NCDR. <i>International Journal of Cardiology</i> , 2020, 305, 44-49.	1.7	4
45	Atrial fibrillation in patients with heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2020, 35, 260-270.	1.8	1
46	Management of Arrhythmias in Cardiac Amyloidosis. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 351-361.	3.2	77
47	Intraluminal Esophageal Temperature Monitoring Using the CircaS-Cath <sup>®</sup> Temperature Probe to Guide Left Atrial Ablation in Patients with Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2386.	0.5	3
48	Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3082-3099.	2.8	21
49	Left Atrial Appendage Electrical Isolation as a Target in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 407-416.	3.2	20
50	Valvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3360-3361.	2.8	3
51	Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. <i>JAMA Network Open</i> , 2019, 2, e1913553.	5.9	7
52	Meta-analysis of Effect of Modest (≈10%) Weight Loss in Management of Overweight and Obese Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1568-1574.	1.6	21
53	Adaptive cardiac resynchronization therapy is associated with decreased risk of incident atrial fibrillation compared to standard biventricular pacing: A real-world analysis of 37,450 patients followed by remote monitoring. <i>Heart Rhythm</i> , 2019, 16, 983-989.	0.7	21
54	The Heart Rhythm Society/American College of Physicians Atrial Fibrillation Screening and Education Initiative. <i>Heart Rhythm</i> , 2019, 16, e59-e65.	0.7	11

#	ARTICLE	IF	CITATIONS
55	Predictors of rate-adaptive pacing in patients implanted with implantable cardioverter-defibrillator and subsequent differential clinical outcomes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 83-91.	1.3	1
56	Clinical implications of redefining recurrence of atrial fibrillation following catheter ablation. <i>Europace</i> , 2019, 21, 1139-1139.	1.7	1
57	Long-term mode and timing of premature ventricular complex recurrence following successful catheter ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 153-160.	1.3	6
58	Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 339-345.	1.8	15
59	Letter by Aldaas et al Regarding Article, "Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study". <i>Circulation</i> , 2019, 139, 144-145.	1.6	0
60	Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. <i>Heart Rhythm</i> , 2019, 16, 733-740.	0.7	13
61	Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice. <i>Heart Rhythm</i> , 2019, 16, e3-e16.	0.7	18
62	Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2019, 123, 187-195.	1.6	9
63	Randomized controlled trial of Amigo <sup>®</sup> robotically controlled versus manually controlled ablation of the cavo-tricuspid isthmus using a contact force ablation catheter. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 51, 125-132.	1.3	2
64	Arrhythmia care in a value-based environment: Past, present, and future. <i>Heart Rhythm</i> , 2018, 15, e5-e15.	0.7	8
65	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 301-310.	4.7	25
66	Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. <i>Europace</i> , 2018, 20, 1412-1419.	1.7	17
67	Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. <i>American Heart Journal</i> , 2018, 200, 24-31.	2.7	41
68	Beyond Pulmonary Vein Isolation During Catheter Ablation in Atrial Fibrillation and Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1292-1293.	2.8	0
69	Coronary Venous Dissection from Left Ventricular Lead Placement During Cardiac Resynchronization Therapy With Defibrillator Implantation and Associated in-Hospital Adverse Events (from the NCDR ICD) <a href="#">Tj ETQq1 1106784314 rgBT /Ove</a>		
70	Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. <i>American Heart Journal</i> , 2018, 195, 50-59.	2.7	20
71	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2018, 121, 131-140.	1.6	15
72	Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. <i>Heart Rhythm</i> , 2018, 15, 847-854.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. <i>Clinical Cardiology</i> , 2018, 41, 1395-1402.	1.8	23
74	The Smartwatch Will See You Now. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1433-1434.	2.8	7
75	Current and Future Use of Insertable Cardiac Monitors. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1383-1396.	3.2	46
76	Successful ventricular tachycardia ablation in a patient with a biventricular ventricular assist device and heparin-induced thrombocytopenia using bivalirudin. <i>HeartRhythm Case Reports</i> , 2018, 4, 367-370.	0.4	4
77	Response to: "Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High-Risk Patients With Atrial Fibrillation and Flutter". <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 615-615.	4.7	0
78	A Cautionary Tone Before Expanded Adoption of the Proposed CHA <sub>2</sub> DS <sub>2</sub> -VASc R Score. <i>Journal of the American College of Cardiology</i> , 2017, 69, 251.	2.8	1
79	Concealed Accessory Pathways with a Single Ventricular and Two Discrete Atrial Insertion Sites. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 255-263.	1.2	6
80	The Relationship of Antitachycardia Pacing versus Shock in an Implantable Cardioverter-Defibrillator Population and the Risk of Mortality: Just an Association?. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 423-424.	1.7	1
81	Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2475-2484.	2.8	220
82	Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS <sub>2</sub> to the CHA <sub>2</sub> DS <sub>2</sub> -VASc Score for Thromboembolic Risk Assessment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	60
83	Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. <i>International Journal of Cardiology</i> , 2017, 243, 263-269.	1.7	9
84	Factors associated with rhythm control treatment decisions in patients with atrial fibrillation—Insights from the NCDR PINNACLE registry. <i>American Heart Journal</i> , 2017, 187, 88-97.	2.7	10
85	A surgeon with symptomatic ventricular tachycardia while operating and exacerbated by left lateral decubitus position: Too much of a stretch?. <i>HeartRhythm Case Reports</i> , 2017, 3, 210-214.	0.4	2
86	Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate?. <i>JAMA Cardiology</i> , 2017, 2, 1397.	6.1	0
87	Clinical Applications of Biomarkers in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 1351-1357.	1.5	39
88	Cardiac Tamponade From Permanent Pacemaker Implantation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 47-49.	3.2	2
89	Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 20-28.	3.2	14
90	Reasons for and predictors of acute hospitalization versus elective outpatient implantable cardioverter-defibrillator implantation and subsequent differential clinical outcomes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 85-93.	1.3	1



#	ARTICLE	IF	CITATIONS
91	The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 724-729.	1.7	13
92	Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2700-2701.	2.8	0
93	Reversal agents for direct oral anticoagulants: A focused review. <i>International Journal of Cardiology</i> , 2016, 223, 244-250.	1.7	10
94	Overtreatment of Low-Risk Patients With Atrial Fibrillationâ€”The Quality Coin Has 2 Sidesâ€”Reply. <i>JAMA Cardiology</i> , 2016, 1, 849.	6.1	0
95	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2493.	2.8	2
96	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	18
97	Cardiac Device Implant Skin Closure with a Novel Adjustable, Coaptive Tapeâ€Based Device. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1077-1082.	1.2	11
98	Compatibility of Radiofrequency Surgical Sponge Detection Technology with Cardiac Implantable Electronic Devices and Temporary Pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1254-1260.	1.2	4
99	Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patientsâ€Risk for Stroke. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2913-2923.	2.8	119
100	Natriuretic Peptides for Predicting LeftâAtrial Reverse Remodeling After AtrialâFibrillation Ablation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 159-161.	3.2	2
101	Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk. <i>JAMA Cardiology</i> , 2016, 1, 55.	6.1	249
102	Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. <i>Heart Rhythm</i> , 2016, 13, e222-e237.	0.7	16
103	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1624-1638.	2.8	43
104	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. <i>Circulation</i> , 2016, 133, e575-86.	1.6	42
105	Nonâ€Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. <i>Clinical Cardiology</i> , 2015, 38, 684-691.	1.8	6
106	Clinical and electrocardiographic characteristics of idiopathic ventricular arrhythmias with right bundle branch block and superior axis: Comparison of apical crux area and posterior septal left ventricle. <i>Heart Rhythm</i> , 2015, 12, 1137-1144.	0.7	25
107	Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal Versus Persistent Atrial Fibrillation. <i>American Journal of Medicine</i> , 2015, 128, 654.e1-654.e10.	1.5	41
108	Utilization trends and clinical outcomes in patients implanted with a single- vs a dual-coil implantable cardioverter-defibrillator lead: Insights from the ALTITUDE Study. <i>Heart Rhythm</i> , 2015, 12, 1770-1775.	0.7	23

#	ARTICLE	IF	CITATIONS
109	Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism. <i>JAMA Internal Medicine</i> , 2015, 175, 1062.	5.1	21
110	Procedure timing as a predictor of in-hospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2015, 169, 45-52.e3.	2.7	12
111	Impact of a 4q25 Genetic Variant in Atrial Flutter and on the Risk of Atrial Fibrillation After Cavotricuspid Isthmus Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 271-277.	1.7	11
112	Safety of radiofrequency catheter ablation without coronary angiography in aortic cusp ventricular arrhythmias. <i>Heart Rhythm</i> , 2014, 11, 1117-1121.	0.7	43
113	Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 256-264.	2.8	32
114	Consideration of patient age and life expectancy in implantable cardioverter-defibrillator referral. <i>American Heart Journal</i> , 2013, 166, 164-170.e5.	2.7	6
115	Atrial Fibrillation and Atrial Flutter in Human Immunodeficiency Virus-Infected Persons. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2288-2295.	2.8	85
116	Elevated pulmonary artery systolic pressures are associated with a lower risk of atrial fibrillation following lung transplantation. <i>Journal of Electrocardiology</i> , 2013, 46, 38-42.	0.9	20
117	Trainee inexperience is associated with longer procedure times but no increase in complications for cardiac device implantation. <i>Heart Rhythm</i> , 2013, 10, 1755-1758.	0.7	8
118	Cardiac Perforation From Implantable Cardioverter-Defibrillator Lead Placement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 582-590.	2.2	60
119	Randomized Trial of Conventional Transseptal Needle Versus Radiofrequency Energy Needle Puncture for Left Atrial Access (the TRAVERSE-ÅLA Study). <i>Journal of the American Heart Association</i> , 2013, 2, e000428.	3.7	52
120	Esophageal Temperature Monitoring During AF Ablation: Multi-ÅSensor or Single-ÅSensor Probe?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, E24.	1.7	2
121	Predictors of Super-Response to Cardiac Resynchronization Therapy and Associated Improvement in Clinical Outcome. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2366-2373.	2.8	252
122	Colchicine After Pulmonary Vein Isolation to Prevent the Early Recurrence of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1797-1798.	2.8	3
123	Low Body Mass Index but Not Obesity Is Associated With In-ÅHospital Adverse Events and Mortality Among Implantable Cardioverter-ÅDefibrillator Recipients: Insights From the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , 2012, 1, e003863.	3.7	24
124	Predictors of Fluoroscopy Time and Procedural Failure During Biventricular Device Implantation. <i>American Journal of Cardiology</i> , 2012, 110, 240-245.	1.6	7
125	Predictors of Unusual ECG Characteristics in Cavotricuspid Isthmus-ÅDependent Atrial Flutter Ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1251-1257.	1.2	4
126	Predictors of Axillary Vein Location for Vascular Access during Pacemaker and Defibrillator Lead Implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1585-1592.	1.2	16



#	ARTICLE	IF	CITATIONS
127	An Unusual Case of Pacemaker Malfunction. <i>Cardiac Electrophysiology Clinics</i> , 2010, 2, 285-288.	1.7	0
128	Differences in accessory pathway location by sex and race. <i>Heart Rhythm</i> , 2010, 7, 52-56.	0.7	26
129	Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. <i>Heart Rhythm</i> , 2006, 3, 1196-1201.	0.7	69